Results 31 to 40 of about 657,649 (153)
Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
, 2020 Background: TRK inhibition is the standard of care for patients with TRK fusion-positive solid tumors. TRK kinase domain mutations that impair drug binding are common mechanisms of resistance to 1st-generation TRK inhibitors.
Toska, Eneda +49 more
core +1 more source
, 2018 Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, and TrkC).
Peter J. Bungay (1586137) +29 more
core +2 more sources
Neurobiology of Disease, 2009 Administration of epidermal growth factor receptor (EGFR) inhibitors (e.g. AG1478/PD168393) promotes central nervous system (CNS) axon regeneration in vivo by an unknown mechanism.
Zubair Ahmed +3 more
doaj +1 more source
Медицинский совет, 2022 The Advisory Board was held on December 24, 2021. The molecular genetic research lead specialists and national lead oncologists discussed issues of diagnosis of NTRK gene translocations in patients with non-small cell lung cancer (NSCLC), as well as ...
E. V. Artamonova +13 more
doaj +1 more source
Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases
, 2016 The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-aminopyrazolylpyrimidine chemotype. Initial optimization
Michelle L. Lamb (1545151) +21 more
core +1 more source
Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
Scientific Reports, 2021 In the last two decades, various therapies have been introduced for lung carcinoma patients, including tyrosine-kinase inhibitors for different mutations. While some of them are specific to specific tumor types, others, like NTRK1–3 fusions, are found in
Simon Strohmeier +5 more
doaj +1 more source
The role of NTRK gene fusions in the biology and treatment of solid tumors
Oncology in Clinical PracticeNTRK gene fusions are rare but crucial oncogenic drivers across various solid tumors. They are more frequent in rare cancers, such as secretory carcinomas and found less commonly in common malignancies such as colorectal cancer, NSCLC, thyroid carcinoma,
Wojciech Kopyciński +6 more
doaj +1 more source
EJNMMI Research, 2022 Background Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are a family of tyrosine kinases primarily expressed in neuronal cells of the brain. Identification of oncogenic alterations in Trk expression as a driver in multiple tumor types has increased ...
Melinda Wuest +7 more
doaj +1 more source
NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
Pathology and Oncology Research, 2022 Targeting molecular alterations has been proven to be an inflecting point in tumor treatment. Especially in recent years, inhibitors that target the tyrosine receptor kinase show excellent response rates and durable effects in all kind of tumors that ...
Vasiliki Siozopoulou +11 more
doaj +1 more source
Case Report: Novel findings of larotrectinib in children with NTRK-rearranged spindle cell tumor
Frontiers in OncologyNeurotrophic tropomyosin receptor kinase (NTRK)-rearranged spindle cell tumors are often resistant to chemotherapy and radiotherapy. Fortunately, they are sensitive to targeted therapy of tropomyosin receptor kinase (TRK) inhibitors. However, the data on
Linnan Wu +11 more
doaj +1 more source